ASH 2020: Asciminib Superior to Bosutinib for Tyrosine Kinase-Resistant Chronic Myeloid Leukemia
This novel investigational therapy may be a new treatment option for patients who do not respond to tyrosine kinase inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.